| 查看: 436 | 回复: 0 | ||
西点6688木虫 (正式写手)
|
[求助]
各位大神，求助一段话的翻译，谢谢！~荟萃分析
|
|
RESULT We summarized 20 trials carried out in metastatic melanoma (MM), non-small cell lung cancer (NSCLC), and renal cell carcinoma (RCC) patients receiving anti-PD-1/PD-L1 antibodies (4230 MM, 1417 NSCLC and 312 RCC patients). Positive PD-L1 MM patients showed a significant decrease (53%) in the risk of mortality vs. negative cases with no heterogeneity. Furthermore, SORRs were 45% and 27% in PD-L1 positive and negative patients, respectively, and SOR indicates a significant difference in term of responses: 2.14 (95% CI: 1.65, 2.77), with low between-study heterogeneity (I2= 35%). Furthermore, results from randomized clinical trials on MM showed that PD-L1 expression is significantly associated with greater clinical response rates to anti-PD1 treatments (SOR 1.89; 95%CI: 1.35, 2.64) but not to other treatments (SOR 0.96; 95%CI: 0.5, 1.87). 因为是荟萃学分析，有些术语不理解，望专业人士点播，谢谢！原文网址： https://www.ncbi.nlm.nih.gov/pubmed/26895815 |
回复此楼» 猜你喜欢
2026年国自然面上资助率
已经有3人回复
-
微信指数没变化，科研之友没阅读
已经有16人回复
-
小木虫看见有人已经知道结果了
已经有17人回复
-
系统今天又提示维护了，估计离放榜不远了
已经有12人回复
-
今年的WR进展到哪一步了？
已经有9人回复
-
产物和副产物价值比较
已经有5人回复
-
时间戳他又来了
已经有17人回复
-
这个自发加氧反应的机理是什么？
已经有7人回复
-
J-J-W不为人知的一面
已经有19人回复
-
没消息就是被刷了呗
已经有14人回复
